Posted on 8/1/2013 11:00 AM
MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole. The MMS Holdings team offers an efficient, adaptable model that enables increased productivity, enhances internal and external reporting, and allows sponsors more time to focus on strategy rather than day-to-day activities. MMS Holdings has strong processes and systems in place as well as experienced, qualified staff, producing a comprehensive pharmacovigilance and risk management solution.
“We are excited to begin this work with Knopp Biosciences and see this as an excellent organizational match. Our team will bring top offerings in the pharmacovigilance area, including delivery of a software solution, Oracle Argus Safety,” says Kelly Hill, Director of Project & Account Management at MMS Holdings Inc. “There is no ‘one-size fits all’ solution. Knopp understands this, and has asked for a specialized solution to best meet their needs. We are glad to meet this request.”
About Knopp Biosciences
Knopp Biosciences, based in Pittsburgh, PA, is a drug discovery and development company focused on delivering breakthrough treatments for unmet needs in neurology and immunology. The company is advancing clinical-stage programs in amyotrophic lateral sclerosis and eosinophil-associated disorders and preclinical programs in epilepsy and neuropathic pain. For more information visit:http://www.knoppneurosciences.com/
About MMS Holdings Inc.
MMS Holdings Inc. is a global clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries. Our strong industry experience and scientific approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards. MMS’ clients span from top 10 pharma to virtual biotech’s, and we support each one with the same standard of excellence. Our core service areas include Data Management, Biostatistics, Clinical Programming, Medical and Regulatory Writing, Pharmacovigilance, Clinical Trial Disclosure and Oncology Data Abstraction. Commitment to quality deliverables sets MMS apart from traditional service providers. MMS is the only CRO to be ISO 9001 certified for all services since inception and we maintain detailed quality metrics for every project. For more information visit:http://www.mmsholdings.com